Clinical Trial Update: Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for rovalpituzumab tesirine in third-line and later Delta-like protein 3-expressing small cell lung cancer; results posted after completion…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• rovalpituzumab tesirine (rovalpituzumab tesirine)

Snippet

Sponsor: AbbVie | Conditions: Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-10-23